FDA Accepts Supplement for Metformin Hydrochloride by MPP Pharma
The FDA has accepted the supplemental application ANDA203832 for Metformin Hydrochloride submitted by MPP Pharma.
Company
Pharmaceutical intelligence for MPP Pharma with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.